Hepatocellular Carcinoma News and Research RSS Feed - Hepatocellular Carcinoma News and Research

Can-Fite BioPharma reports financial results, provides update on drug development programs

Can-Fite BioPharma reports financial results, provides update on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2016 and updates on its drug development programs. [More]
Low selenium levels linked to liver cancer risk? An interview with Dr David Hughes

Low selenium levels linked to liver cancer risk? An interview with Dr David Hughes

Food provides us with a variety of substances we need to maintain life. These substances are essential nutrients and are classified as macronutrients (water, protein, fats, and carbohydrates) and micronutrients (vitamins and minerals). [More]
Sleep-disordered breathing promotes progression of pediatric NAFLD to NASH

Sleep-disordered breathing promotes progression of pediatric NAFLD to NASH

Studies have shown that obstructive sleep apnea and low nighttime oxygen, which result in oxidative stress, are associated with the progression of non-alcoholic fatty liver disease (NAFLD) in adults. [More]
New method helps characterize immune cells in tumor tissues

New method helps characterize immune cells in tumor tissues

Despite recent achievements in the development of cancer immunotherapies, only a small group of patients typically respond to them. Predictive markers of disease course and response to immunotherapy are urgently needed. [More]
Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two decades. [More]
Low levels of blood selenium may increase risk of liver cancer

Low levels of blood selenium may increase risk of liver cancer

A new study, published in current issue of The American Journal of Clinical Nutrition, shows that the highest levels of blood selenium or of selenoprotein P, the protein that distributes selenium from the liver around the body, are associated with a decreased risk of developing liver cancer (particularly hepatocellular carcinoma), even when all other major liver cancer risk factors are taken into account. [More]
CNIO study shows proinflammatory molecule IL-17A can be key factor in development of NASH and HCC

CNIO study shows proinflammatory molecule IL-17A can be key factor in development of NASH and HCC

Non-alcoholic steatohepatitis (NASH) is a serious hepatic condition that precedes hepatocellular carcinoma (HCC) and is currently untreatable. [More]
FIB-4 index predicts HBV-related HCC

FIB-4 index predicts HBV-related HCC

Japanese researchers reveal an association between elevated FIB-4 index 24 weeks after the initiation of nucleos(t)ide analogue therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. [More]
Infant HBV vaccination prevents HCC in children, young adults

Infant HBV vaccination prevents HCC in children, young adults

Immunisation against hepatitis B virus in infants protects against the development of hepatocellular carcinoma in not only children but also young adults, a Taiwanese study finds. [More]
Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Oral multikinase inhibitor regorafenib achieves significantly improved survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase III RESORCE trial, presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [More]
HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

In patients with chronic hepatitis B virus infection who have been newly diagnosed with cirrhosis, the risk of hepatocellular carcinoma development can be ascertained using several clinical and molecular factors, study findings indicate. [More]
Novel enzyme immunoassay helps diagnose HCV infection in one simple step

Novel enzyme immunoassay helps diagnose HCV infection in one simple step

The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient, time consuming, and globally not widely available or affordable. [More]
Panel of microRNAs can predict patients at risk for developing HBV-driven liver cancer

Panel of microRNAs can predict patients at risk for developing HBV-driven liver cancer

Hepatocellular carcinoma, the most common type of liver cancer, is increasing in incidence in the United States, and infection with the Hepatitis B virus (HBV) causes about 50 percent of cases. [More]
Scientists debate role of AAV in causing hepatocellular carcinoma

Scientists debate role of AAV in causing hepatocellular carcinoma

Liver cancer can be triggered by mutations in cancer driver genes resulting from the insertion of adeno-associated virus (AAV) vectors used to deliver therapeutic genes, although this tumor-inducing role of AAV remains highly controversial. [More]
Researchers discover new potential treatment target for liver cancer

Researchers discover new potential treatment target for liver cancer

Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer. [More]
High levels of p62 protein in liver linked to cancer recurrence

High levels of p62 protein in liver linked to cancer recurrence

Researchers at University of California San Diego School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have discovered that high levels of the protein p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival. [More]
FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. [More]
MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

The Medical University of South Carolina's Hollings Cancer Center received an $8.9 million grant from the National Cancer Institute designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a class of lipids known to be involved in the growth of solid tumor cancers. [More]

High-level quantum chemical computations help unravel underlying mechanism of hepatocellular toxicity

Balasubramanian and Basak have recently reported quantum chemical computations that enhance our understanding of mechanisms for the causes of liver toxicity. Hepatocellular carcinoma is one of the most common forms of cancer, and the primary cause has been attributed to liver fibrosis by chemical toxins, which is followed by liver cirrhosis. [More]

Antiviral therapies equal survival rate of HCV-related cirrhosis patients with general population

The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology. [More]
Advertisement